sorafenib has been researched along with entinostat in 4 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (entinostat) | Trials (entinostat) | Recent Studies (post-2010) (entinostat) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 557 | 31 | 402 |
| Protein | Taxonomy | sorafenib (IC50) | entinostat (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 1.5547 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.73 | |
| Tissue factor | Homo sapiens (human) | 8 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 3.93 | |
| Histone deacetylase 4 | Homo sapiens (human) | 2.5077 | |
| Histone deacetylase 1 | Homo sapiens (human) | 1.0631 | |
| Histone deacetylase 7 | Homo sapiens (human) | 2.7679 | |
| Histone deacetylase 2 | Homo sapiens (human) | 1.4517 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 3.1451 | |
| Histone deacetylase 11 | Homo sapiens (human) | 3.3762 | |
| Histone deacetylase 8 | Homo sapiens (human) | 3.5118 | |
| Histone deacetylase 6 | Homo sapiens (human) | 2.9645 | |
| Histone deacetylase 9 | Homo sapiens (human) | 2.9949 | |
| Histone deacetylase 5 | Homo sapiens (human) | 2.7109 | |
| Histone deacetylase | Plasmodium falciparum (malaria parasite P. falciparum) | 0.94 | |
| Nuclear receptor corepressor 2 | Homo sapiens (human) | 1.185 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM | 1 |
| Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D | 1 |
| Adjei, AA; Brady, W; DePaolo, D; Ding, Y; Dy, GK; Fetterly, G; Ma, WW; Ngamphaiboon, N; Reungwetwattana, T; Zhao, Y | 1 |
1 review(s) available for sorafenib and entinostat
| Article | Year |
|---|---|
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors | 2021 |
1 trial(s) available for sorafenib and entinostat
| Article | Year |
|---|---|
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Female; Histone Deacetylase Inhibitors; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2015 |
2 other study(ies) available for sorafenib and entinostat
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzamides; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Gemcitabine; Histone Deacetylase Inhibitors; Humans; L-Lactate Dehydrogenase; Niacinamide; Phenylurea Compounds; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyridines; Sorafenib | 2007 |